Skip to content
    Reviews

    First-Line Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma

    Valsecchi et alCancer and Metastasis Reviews

    First-Line Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma
    A systematic review by the Meet-URO group analyzed molecular and circulating biomarker data across 16 reports from phase III randomized clinical trials evaluating first-line immune checkpoint inhibitor (ICI)–based combinations in metastatic clear cell renal cell carcinoma (mRCC). PD-L1 expression failed to reliably discriminate clinical benefit across ICI regimens overall, though it conferred a negative prognostic impact in sunitinib-treated cohorts and a potential predictive signal for nivolumab plus ipilimumab. High angiogenic gene expression signatures consistently correlated with favorable prognostic outcomes across therapies but predicted minimal additional benefit from adding ICIs, whereas immune-related signatures were specifically linked to ICI responsiveness. Proliferation and MYC-related gene signatures identified high-risk disease with adverse outcomes regardless of treatment type. Individual gene mutations (including PBRM1, VHL, BAP1, and PTEN) exhibited heterogeneous and primarily prognostic value, whereas composite genomic panels (such as rDM) and circulating markers (including inflammatory cytokines and longitudinal KIM-1 dynamics) demonstrated stronger predictive potential. Despite these findings, no single or composite biomarker is currently validated to direct first-line treatment selection in clinical practice.

    Key Takeaways

    • Currently, no validated molecular or circulating biomarker is clinically established to guide treatment selection among first-line immune checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.
    • Tumors with high angiogenic transcriptomic signatures are consistently associated with improved outcomes across treatment arms but derive limited additional benefit from the addition of immune checkpoint inhibitors.
    • PD-L1 expression demonstrates a negative prognostic effect in patients treated with sunitinib and exhibits potential predictive utility specifically for nivolumab plus ipilimumab.
    Read the original sourceCancer and Metastasis Reviews